Back to Search Start Over

Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial

Source :
Legal Monitor Worldwide. October 30, 2020
Publication Year :
2020

Abstract

(GlobeNewswire) - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has received a Study May Proceed letter [...]

Subjects

Subjects :
United States. Food and Drug Administration -- Planning
Biocon Ltd. -- Planning
Clinical trials
Adult respiratory distress syndrome
COVID-19
Company business planning
Business, international
Law

Details

Language :
English
Database :
Gale General OneFile
Journal :
Legal Monitor Worldwide
Publication Type :
News
Accession number :
edsgcl.639899028

Tools

Authors Abstract Subjects Details